Rigel Pharmaceuticals (NASDAQ:RIGL) specializes in discovering, developing, and marketing novel small molecule drugs for the treatment of rare diseases. The company focuses on immunology, oncology, and immune-oncology programs. Their pipeline is rich with projects aiming to target various diseases with unmet medical needs, working on both internally discovered and externally sourced compounds. Objectives include advancing their research to bring innovative therapies to patients while pursuing strategic partnerships and collaborations to expand their reach and capabilities. With a commitment to scientific excellence, Rigel Pharmaceuticals aims to improve the lives of patients suffering from rare and serious diseases through cutting-edge research and drug development.